JP2020533273A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533273A5
JP2020533273A5 JP2020503686A JP2020503686A JP2020533273A5 JP 2020533273 A5 JP2020533273 A5 JP 2020533273A5 JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020533273 A5 JP2020533273 A5 JP 2020533273A5
Authority
JP
Japan
Prior art keywords
polypeptide
tmmp
amino acid
mutant
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020503686A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049756 external-priority patent/WO2019051091A1/en
Publication of JP2020533273A publication Critical patent/JP2020533273A/ja
Publication of JP2020533273A5 publication Critical patent/JP2020533273A5/ja
Pending legal-status Critical Current

Links

JP2020503686A 2017-09-07 2018-09-06 多量体t細胞調節ポリペプチドおよびその使用方法 Pending JP2020533273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555499P 2017-09-07 2017-09-07
US62/555,499 2017-09-07
PCT/US2018/049756 WO2019051091A1 (en) 2017-09-07 2018-09-06 T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF

Publications (2)

Publication Number Publication Date
JP2020533273A JP2020533273A (ja) 2020-11-19
JP2020533273A5 true JP2020533273A5 (OSRAM) 2021-10-28

Family

ID=65634643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020503686A Pending JP2020533273A (ja) 2017-09-07 2018-09-06 多量体t細胞調節ポリペプチドおよびその使用方法

Country Status (12)

Country Link
US (4) US20200148744A1 (OSRAM)
EP (1) EP3678691A4 (OSRAM)
JP (1) JP2020533273A (OSRAM)
KR (1) KR20200040860A (OSRAM)
CN (1) CN111050793A (OSRAM)
AU (1) AU2018328280B2 (OSRAM)
BR (1) BR112020004535A2 (OSRAM)
CA (1) CA3070484A1 (OSRAM)
EA (1) EA202090471A1 (OSRAM)
IL (2) IL297361B2 (OSRAM)
MX (1) MX2020002596A (OSRAM)
WO (1) WO2019051091A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505591B2 (en) * 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
TW201920249A (zh) * 2017-09-07 2019-06-01 美商信號生物製藥公司 具有結合位點之t細胞調節多聚體多肽及其使用方法
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體t細胞調節多肽及其使用方法
EP3719033A1 (en) 2019-04-02 2020-10-07 imusyn GmbH & Co. KG Stabilized mhc i
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ, インコーポレイテッド 多量体t細胞調節性ポリペプチド及びその使用方法
WO2021102063A1 (en) 2019-11-20 2021-05-27 Anwita Biosciences, Inc. Cytokine fusion proteins, and their pharmaceutical compositions and therapeutic applications
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
AU2021239772A1 (en) * 2020-03-18 2022-09-15 Gi Innovation, Inc. Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
CN111592580A (zh) * 2020-05-08 2020-08-28 中国药科大学 一种具有免疫检查点ctla-4抑制活性的多肽及其应用
EP4149953A4 (en) * 2020-05-12 2024-06-26 Lg Chem, Ltd. MULTIMER T CELL MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
KR20230052881A (ko) * 2020-07-14 2023-04-20 큐 바이오파마, 인크. 접합 부위를 갖는 t-세포 조절 폴리펩티드 및 이의 사용 방법
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN113424794B (zh) * 2021-04-16 2022-07-26 安徽农业大学 一种优质抗病型地方鸡新品系选育方法
IL315362A (en) * 2022-03-01 2024-11-01 Crosslink Therapeutics Inc ATP-dependent agonists of immune cells function as anticancer agents
EP4709743A1 (en) * 2023-05-11 2026-03-18 Immudex ApS Mhc class i molecules

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
SG11201605632SA (en) * 2014-01-21 2016-08-30 Einstein Coll Med Cellular platform for rapid and comprehensive t-cell immunomonitoring
PT3480213T (pt) * 2014-06-18 2020-02-04 Albert Einstein College Medicine Polipéptidos syntac e utilizações dos mesmos

Similar Documents

Publication Publication Date Title
Korman et al. The foundations of immune checkpoint blockade and the ipilimumab approval decennial
JP2022534846A5 (OSRAM)
Triebel LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination
Touloukian et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
JP2021500855A5 (OSRAM)
KR102436129B1 (ko) T 세포 수용체 및 이의 용도
JP6722189B2 (ja) 単量体Fcドメイン
Tutt et al. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
KR20220066075A (ko) T-세포 조절 폴리펩타이드 및 이의 사용 방법
JP2022515331A5 (OSRAM)
JP2020514375A5 (OSRAM)
IL272085B2 (en) Multimeric t-cell modulatory polypeptides and methods of use thereof
US20160199479A1 (en) T cell receptors
JP2022548472A5 (OSRAM)
JP2021500855A (ja) 抗原提示ポリペプチドおよびその使用方法
Casares et al. Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation
JP2018524326A5 (OSRAM)
CN115103852A (zh) Prame tcr受体和其用途
CN110088126A (zh) Icos配体变体免疫调节蛋白及其用途
JP2024512470A (ja) T細胞調節ポリペプチド及びその使用方法
JP2022515331A (ja) 多量体t細胞調節ポリペプチド及びその使用方法
O’Herrin et al. Antigen-specific blockade of T cells in vivo using dimeric MHC peptide
JP2022536581A5 (OSRAM)
CA3149583A1 (en) Chimeric proteins in autoimmunity
WO2020132366A4 (en) T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof